Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial.

What the trial testedrandomised · 30 people · 2021

Randomised comparison

−6.00mmol/mol−9.70 to −2.20

As reported

difference −6.0 mmol/mol, 95% CI −9.70 to −2.20

Not counted

−4.40percentage points−8.20 to −0.70

As reported

difference −4.4 %, 95% CI −8.20 to −0.70

the abstract, start to end

… change from baseline: EXE + DAPA -4.4%, 95% confidence interval [CI] …

… PLAC + DAPA (adjusted difference: HbA1c -6.0 mmol/mol [95% CI -9.7, -2.2], …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

−4.4−8.20 to −0.70

Glycemic control

−6.0−9.70 to −2.20

SGLT2 inhibitorsGLP-1 receptor agonistsGlycemic controlAdverse events & safety

1 / 4

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it